Danaher Corporation $DHR Position Trimmed by Greenleaf Trust

Greenleaf Trust reduced its holdings in shares of Danaher Corporation (NYSE:DHR) by 2.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 82,518 shares of the conglomerate’s stock after selling 2,365 shares during the period. Greenleaf Trust’s holdings in Danaher were worth $18,282,000 as of its most recent filing with the SEC.

Other hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Danaher in the second quarter valued at $10,492,520,000. Wellington Management Group LLP grew its holdings in Danaher by 10.4% during the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after acquiring an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC bought a new stake in Danaher during the second quarter valued at $1,456,317,000. Generation Investment Management LLP bought a new stake in Danaher in the second quarter valued at $1,287,949,000. Finally, Bank of America Corp DE acquired a new position in Danaher during the 2nd quarter worth $993,846,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Down 0.0%

DHR stock opened at $232.22 on Monday. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The firm has a market capitalization of $163.37 billion, a PE ratio of 38.01, a PEG ratio of 2.92 and a beta of 0.76. The business’s 50 day simple moving average is $218.92 and its 200 day simple moving average is $201.77. The company has a current ratio of 1.63, a quick ratio of 1.29 and a debt-to-equity ratio of 0.45.

Danaher (NYSE:DHR) last announced its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, topping the consensus estimate of $1.92 by $0.19. The business had revenue of $6.55 billion during the quarter, compared to the consensus estimate of $6.56 billion. Danaher had a net margin of 16.91% and a return on equity of 11.17%. Danaher’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.89 EPS. As a group, research analysts anticipate that Danaher Corporation will post 8.59 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Wednesday, September 30th. Danaher’s dividend payout ratio is presently 26.19%.

Insider Buying and Selling

In other Danaher news, CAO Christopher Bouda sold 7,598 shares of Danaher stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $234.56, for a total value of $1,782,186.88. Following the completion of the transaction, the chief accounting officer directly owned 9,107 shares of the company’s stock, valued at $2,136,137.92. The trade was a 45.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have issued reports on DHR. JPMorgan Chase & Co. boosted their price objective on Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a report on Thursday, October 22nd. Evercore reiterated an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. UBS Group reissued a “buy” rating and set a $260.00 price objective on shares of Danaher in a report on Thursday, October 22nd. Royal Bank Of Canada upped their target price on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Finally, DZ Bank downgraded Danaher from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Eighteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus price target of $242.91.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.